Urology A device for treating BPH using microwave heat without injuring adjacent healthy tissue with TUMT®–transurethral microwave thermotherapy. See Benign prostatic hypertrophy.
References in periodicals archive ?
In connection with the company's strategy to develop a next generation catheter, company management recently developed an end-of-life plan for its Prostatron control units and Prostaprobe treatment catheters resulting in a non-cash charge of $6.
Accordingly, it has become evident that the Prostatron line will have a limited future life.
Urologix acquired this patent in 2000 as part of the acquisition of the Prostatron product line from EDAP TMS S.
Urologix markets its products under the Targis and Prostatron names.
The Food and Drug Administration approved the Prostatron, which kills excess prostate tissue by heating the gland with microwaves, based on studies showing it may help 75 percent of patients.
The Prostatron is a one-hour, outpatient procedure that appears to work better than drugs and clearly is safer than surgery, said Dr.
With this support, a healthy supply of both Prostatron and Targis control units, and increased reimbursement in the physician's office and hospital, we anticipate a strong second half of fiscal 2002.
In July 2000 at the Fifth International Consultation for BPH, the World Health Organization recognized TUMT as represented by the Targis and Prostatron systems as an efficacious treatment that can be truly delivered in an outpatient setting such as a physician's office without anesthesia.
Finally, the Company has begun to move forward with its contract manufacturing business based on the successes and knowledge gained from being the contract manufacturer for Urologix's Prostatron system and recently bolstered by a very successful inspection of the Company's lithotripsy manufacturing by the Food and Drug Administration.
HIFU total revenues to double in 2002 versus 2001; -- Urology devices and services division remains consistent with year-over-year revenues with an increase in the number of machines sold in 2002 versus 2001, offset by a decrease in Prostatron orders; -- Continued increases in gross margins as a percent of sales; -- Continued control over recurring operating expenses; and -- Aggressive management of cash flows.
This was partially a result of some of the third party mobile users of Prostatron being converted to the Company's CoolWave technology, as well as the Company transferring some of its Urologix serviced mobile accounts to routes run by third party mobile providers.
The Company also operates Prostatrons to treat benign hyperplasia.